127 related articles for article (PubMed ID: 1741214)
41. Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects.
Amato G; Izzo G; La Montagna G; Bellastella A
Clin Endocrinol (Oxf); 1996 Jul; 45(1):27-32. PubMed ID: 8796135
[TBL] [Abstract][Full Text] [Related]
42. Growth parameters and predictors of growth in short children with and without growth hormone (GH) deficiency treated with human GH: a randomized controlled study.
Soliman AT; abdul Khadir MM
J Trop Pediatr; 1996 Oct; 42(5):281-6. PubMed ID: 8936959
[TBL] [Abstract][Full Text] [Related]
43. Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency.
Bollerslev J; Møller J; Thomas S; Djøseland O; Christiansen JS
Eur J Endocrinol; 1996 Dec; 135(6):666-71. PubMed ID: 9025710
[TBL] [Abstract][Full Text] [Related]
44. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis.
Antoniazzi F; Bertoldo F; Mottes M; Valli M; Sirpresi S; Zamboni G; Valentini R; Tató L
J Pediatr; 1996 Sep; 129(3):432-9. PubMed ID: 8804334
[TBL] [Abstract][Full Text] [Related]
45. Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement.
Ahmad AM; Hopkins MT; Thomas J; Ibrahim H; Fraser WD; Vora JP
Clin Endocrinol (Oxf); 2001 Jun; 54(6):709-17. PubMed ID: 11422104
[TBL] [Abstract][Full Text] [Related]
46. Final height data, body composition and glucose metabolism in growth hormone-treated short children born small for gestational age.
Hokken-Koelega AC; van Pareren Y; Sas T; Arends N
Horm Res; 2003; 60 Suppl 3():113-4. PubMed ID: 14671407
[TBL] [Abstract][Full Text] [Related]
47. Effect of long-term growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency.
Kotzmann H; Riedl M; Bernecker P; Clodi M; Kainberger F; Kaider A; Woloszczuk W; Luger A
Calcif Tissue Int; 1998 Jan; 62(1):40-6. PubMed ID: 9405732
[TBL] [Abstract][Full Text] [Related]
48. Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field.
Sartorio A; Marazzi N; Agosti F; Faglia G; Corradini C; De Palo E; Cella S; Rigamonti A; Muller EE
J Endocrinol Invest; 2004 May; 27(5):410-5. PubMed ID: 15279071
[TBL] [Abstract][Full Text] [Related]
49. Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and response to GH therapy.
Tobiume H; Kanzaki S; Hida S; Ono T; Moriwake T; Yamauchi S; Tanaka H; Seino Y
J Clin Endocrinol Metab; 1997 Jul; 82(7):2056-61. PubMed ID: 9215272
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of growth hormone treatment in short children with renal allografts: three year experience. Members of the German Study Group for Growth Hormone Treatment in Children with Renal Allografts.
Tönshoff B; Haffner D; Mehls O; Dietz M; Ruder H; Blum WF; Heinrich U; Stöver B
Kidney Int; 1993 Jul; 44(1):199-207. PubMed ID: 7689125
[TBL] [Abstract][Full Text] [Related]
51. Subcutaneous treatment with growth hormone-releasing hormone for short stature.
Hernández M; Fragoso J; Barrio R; Argente J; Arilla E
Horm Res; 1988; 30(6):252-7. PubMed ID: 2907992
[TBL] [Abstract][Full Text] [Related]
52. GH response to provocation and circulating IGF-I and IGF-binding protein-3 concentrations, the IGF-I generation test and clinical response to GH therapy in children with beta-thalassaemia.
Soliman AT; El Banna N; Ansari BM
Eur J Endocrinol; 1998 Apr; 138(4):394-400. PubMed ID: 9578506
[TBL] [Abstract][Full Text] [Related]
53. European multicentre study in children born small for gestational age with persistent short stature: comparison of continuous and discontinuous growth hormone treatment regimens.
Phillip M; Lebenthal Y; Lebl J; Zuckerman-Levin N; Korpal-Szczyrska M; Marques JS; Steensberg A; Jons K; Kappelgaard AM; Ibanez L;
Horm Res; 2009 Jan; 71(1):52-9. PubMed ID: 19039237
[TBL] [Abstract][Full Text] [Related]
54. Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis.
Saggese G; Pasquino AM; Bertelloni S; Baroncelli GI; Battini R; Pucarelli I; Segni M; Franchi G
Acta Paediatr; 1995 Mar; 84(3):299-304. PubMed ID: 7780252
[TBL] [Abstract][Full Text] [Related]
55. Growth hormone therapy does not alter the insulin-like growth factor-I/insulin-like growth factor binding protein-3 molar ratio in growth hormone-deficient children.
Scirè G; Del Bianco C; Spadoni GL; Cianfarani S
J Endocrinol Invest; 2008 Feb; 31(2):153-8. PubMed ID: 18362507
[TBL] [Abstract][Full Text] [Related]
56. Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency.
Sartorio A; Arosio M; Conti A; Ferrero S; Porretti S; Faglia G
J Endocrinol Invest; 1999 Mar; 22(3):169-75. PubMed ID: 10219883
[TBL] [Abstract][Full Text] [Related]
57. Growth hormone treatment of short stature and metabolic dysfunction in juvenile chronic arthritis.
Simon D; Touati G; Prieur AM; Ruiz JC; Czernichow P
Acta Paediatr Suppl; 1999 Feb; 88(428):100-5. PubMed ID: 10102064
[TBL] [Abstract][Full Text] [Related]
58. Levels of growth hormone, insulin-like growth factor-I (IGF-I) and -II, IGF-binding protein-1 and -3, and cortisol in prednisone-treated children with growth retardation after renal transplantation.
Hokken-Koelega AC; Stijnen T; de Muinck Keizer-Schrama SM; Blum WF; Drop SL
J Clin Endocrinol Metab; 1993 Oct; 77(4):932-8. PubMed ID: 7691864
[TBL] [Abstract][Full Text] [Related]
59. Renal handling of phosphate can predict height velocity during growth hormone therapy for short children.
Nishiyama S; Ikuta M; Nakamura T; Tomoeda S; Matsuda I
J Clin Endocrinol Metab; 1992 Apr; 74(4):906-9. PubMed ID: 1548358
[TBL] [Abstract][Full Text] [Related]
60. Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty.
Lanes R; Gunczler P
Clin Endocrinol (Oxf); 1998 Aug; 49(2):197-202. PubMed ID: 9828907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
